Search Results - "d'Audigier, C"

Underestimation of plasma level of factor V coagulant activity and fibrinogen concentration together with prolonged prothrombin time, activated partial thromboplastin time and thrombin time can result from pre-analytical very low calcium level in citrated sample tube by d'Audigier, C., Delassasseigne, C., Robert, A., Eschwège, V.

“…Summary Introduction Pre‐analytical phase is a critical step in the haemostasis laboratory cycle. Numerous variations affect tests results, and it is crucial…”
Get full text

The profibrotic cytokine transforming growth factor‐β1 increases endothelial progenitor cell angiogenic properties by EVRARD, S. M., D′AUDIGIER, C., MAUGE, L., ISRAËL‐BIET, D., GUERIN, C. L., BIECHE, I., KOVACIC, J. C., FISCHER, A.‐M., GAUSSEM, P., SMADJA, D. M.

“…Background:  Transforming growth factor‐β1 (TGF‐β1) is a profibrotic cytokine that plays a major role in vascular biology, and is known to regulate the…”
Get full text

Angiogenic potential of BM MSCs derived from patients with critical leg ischemia by Smadja, D M, d'Audigier, C, Guerin, C L, Mauge, L, Dizier, B, Silvestre, J-S, Cortivo, L Dal, Gaussem, P, Emmerich, J

Get full text

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 by Spigel, D.R., Vicente, D., Ciuleanu, T.E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Luft, A., Wolf, J., Antonia, S., Nakagawa, K., Fairchild, J., Baudelet, C., Pandya, D., Doshi, P., Chang, H., Reck, M.

“…Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously…”
Get full text

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project by Blons, H., Oudart, J.-B., Merlio, J.-P., Debieuvre, D., de Fraipont, F., Audigier-Valette, C., Escande, F., Hominal, S., Bringuier, P.‐P., Fraboulet-Moreau, S., Ouafik, L., Moro-Sibilot, D., Lemoine, A., Langlais, A, Missy, P., Morin, F., Souquet, P.-J., Barlesi, F., Cadranel, J., Beau‐Faller, M.

“…•Response to EGFR TKI is heterogeneous among patients with EGFR mutated NSCLC.•Routine use of NGS enables co-mutations detection that may impact response to…”
Get full text

Tuberculosis trends in a hot-spot region in Paris, France by Pierre-Audigier, C., Talla, C., Alame-Emane, A-K., Audigier, B., Grall, N., Ruimy, R., Andremont, A., Cadet-Daniel, V., Sola, C., Takiff, H., Gicquel, B., Vray, M., Armand-Lefevre, L.

“…SETTING: Tuberculosis (TB) incidence is declining overall in France, but not in Paris where some areas remain relative hot spots for TB.OBJECTIVES: To obtain a…”
Get full text

Validation of a Bruton's disease genetic analysis method by Rodriguez, C, d'Audigier, C, Bertrand, V

“…Bruton's disease is the most frequently primary X-linked immunodeficiency. Patients are more susceptible to early and recurring infections associated with…”
Get more information

Primary immunodeficiencies and Bruton's disease genetic analysis: which prospects offers this genetic diagnosis? by d'Audigier, C, Rodriguez, C, Bertrand, V

“…Bruton's disease is the most frequently primary X-linked immunodeficiency. Bruton's tyrosine kinase (Btk) is encoded by the XLA gene that when mutated causes…”
Get more information

Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance by Alame-Emane, A. K., Xu, P., Pierre-Audigier, C., Cadet-Daniel, V., Shen, X., Sraouia, M., Siawaya, J. F. Djoba, Takiff, H., Gao, Q., Gicquel, B

“…BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health…”
Get full text

Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients by Pommier, J.D., Ben Lasfar, N., Van Grunderbeeck, N., Burdet, C., Laouénan, C., Rioux, C., Pierre-Audigier, C., Meybeck, A., Choudat, L., Benchikh, A., Nguyen, S., Bouvet, E., Yeni, P., Yazdanpanah, Y., Joly, V.

“…Background: Intravesical bacillus Calmette-Guerin (BCG) therapy is an effective and widely used treatment for superficial bladder carcinoma. Local…”
Get full text

Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis [Short communication] by Pierre-Audigier, C., Surcouf, C., Cadet-Daniel, V., Namouchi, A., Heng, S., Murray, A., Guillard, B., Gicquel, B.

“…In a study performed in Cambodia, a higher number of tuberculosis (TB) strains with mutations in the pncA gene associated with pyrazinamide resistance (PZA-R)…”
Get full text

hsp65 Sequencing for Identification of Rapidly Growing Mycobacteria by Ringuet, H, Akoua-Koffi, C, Honore, S, Varnerot, A, Vincent, V, Berche, P, Gaillard, J L, Pierre-Audigier, C

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study by Auliac, J. B., Fournier, C., Audigier Valette, C., Perol, M., Bizieux, A., Vinas, F., Decroisette Phan van Ho, C., Bota Ouchlif, S., Corre, R., Le Garff, G., Fournel, P., Baize, N., Lamy, R., Vergnenegre, A., Arpin, D., Marin, B., Chouaid, C., Gervais, R.

“…Retrospective studies suggested a benefit of first-line tyrosine kinase inhibitor (TKI) treatment continuation after response evaluation in solid tumors…”
Get full text

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331 by Reck, M., Vicente, D., Ciuleanu, T., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Wolf, J., Antonia, S.J., Nakagawa, K., Selvaggi, G., Baudelet, C., Chang, H., Spigel, D.R.

Get full text

Omicron variant: A clear and present danger for patients with cancer by Barrière, J., Zalcman, G., Fignon, L., Peiffer-Smadja, N., Audigier-Valette, C., Carles, M.

Get full text

HIF‐Prolyl Hydroxylase 2 Inhibition Enhances the Efficiency of Mesenchymal Stem Cell‐Based Therapies for the Treatment of Critical Limb Ischemia by HoWangYin, Kiave-Yune, Loinard, Céline, Bakker, Wineke, Guérin, Coralie L., Vilar, José, D'Audigier, Clément, Mauge, Laetitia, Bruneval, Patrick, Emmerich, Joseph, Lévy, Bernard I., Pouysségur, Jacques, Smadja, David M., Silvestre, Jean‐Sébastien

“…Upregulation of hypoxia‐inducible transcription factor‐1α (HIF‐1α), through prolyl‐hydroxylase domain protein (PHD) inhibition, can be thought of as a master…”
Get full text

Rapid identification of multidrug-resistant tuberculosis isolates in treatment failure or relapse patients in Bangui, Central African Republic [Short communication] by MINIME-LINGOUPOU, F, PIERRE-AUDIGIER, C, KASSA-KELEMBHO, E, BARILONE, N, ZANDANGA, G, RAUZIER, J, CADET-DANIEL, V, LE FAOU, A, GICQUEL, B

“…Multidrug-resistant (MDR) strains were identified in 40% of 54 strains from patients presenting with tuberculosis (TB) treatment failure or relapse in Bangui,…”
Get full text

Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors by Heudel, P.E., de Montfort, A., Debieuvre, D., Chouaid, C., Carton, M., Audigier-Valette, C., Filleron, T., Chabaud, S., Stancu, A., Quantin, X., Hiret, S., Bosquet, L., Blay, J.Y.

“…•This retrospective study included 10 796 AMLC patients allowed to demonstrate that the rate of SPCs is significantly lower on the group of patients treated…”
Get full text

Molecular fingerprinting of Mycobacterium tuberculosis and risk factors for tuberculosis transmission in Paris, France, and surrounding area by GUTIERREZ, M. C, VINCENT, V, PANGON, B, PIERRE-AUDIGIER, C, AUBERT, D, BIZET, J, GAILLOT, O, LEBRUN, L, LE PENDEVEN, C, LE PENNEC, M. P, MATHIEU, D, OFFREDO, C

“…Forty-three percent of the tuberculosis cases reported in France are from the Ile de France region. The incidence of tuberculosis in this region is 33 cases…”
Get full text

Measurement of Immunoglobulin G against Mycobacterial Antigen A60 in Patients with Cystic Fibrosis and Lung Infection Due to Mycobacterium abscessus by Ferroni, Agnès, Sermet-Gaudelus, Isabelle, Bourgeois, Muriel Le, Pierre-Audigier, Catherine, Offredo, Catherine, Rottman, Martin, Guillemot, Didier, Bernède, Claire, Vincent, Véronique, Berche, Patrick, Gaillard, Jean-Louis

“…Background. The diagnosis and prognosis of lung infections due to the emerging nontuberculous mycobacterium (NTM) Mycobacterium abscessus are difficult to…”
Get full text